Form 4: Nektar Therapeutics Chief Legal Officer Sells Shares to Cover Tax Obligations

Mark Andrew Wilson, Chief Legal Officer of Nektar Therapeutics, sold 9,996 shares of common stock on May 19, 2025, to cover tax withholding obligations related to vesting RSUs.

Summary

• On May 19, 2025, Mark Andrew Wilson, the Chief Legal Officer of Nektar Therapeutics, sold 9,996 shares of the company's common stock.
• The sale was executed to cover required tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• The shares were sold at a weighted average price of $0.67, with individual transactions ranging from $0.66 to $0.69.
• Following the transaction, Wilson still beneficially owns 314,296 shares, including 7,107 shares held in the Issuer's ESPP plan.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (sale of shares to cover taxes) and doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and are generally not indicative of the executive's long-term outlook on the company.

Stakeholder Impact

• The sale of shares by a company executive could have a minor negative impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Nektar Therapeutics, NKTR, Mark Andrew Wilson, Chief Legal Officer, Form 4, Share Sale, RSU Vesting, Tax Withholding, ESPP